Co-Authors
This is a "connection" page, showing publications co-authored by JOHN FREDERICK DE GROOT and ERIK PHILIP SULMAN.
Connection Strength
1.093
-
Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers (Basel). 2021 Oct 21; 13(21).
Score: 0.201
-
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget. 2018 Feb 13; 9(12):10497-10509.
Score: 0.154
-
A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget. 2017 Oct 27; 8(52):90488-90495.
Score: 0.152
-
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013 Aug 15; 19(16):4392-403.
Score: 0.113
-
Multigene sets for clinical application in glioma. J Natl Compr Canc Netw. 2011 Apr; 9(4):449-56; quiz 457.
Score: 0.096
-
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro Oncol. 2024 Aug 05; 26(8):1367-1387.
Score: 0.061
-
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.
Score: 0.049
-
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073.
Score: 0.049
-
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021 02 25; 23(2):284-294.
Score: 0.048
-
Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol. 2020 04 15; 22(4):577-579.
Score: 0.045
-
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 03 15; 26(6):1395-1407.
Score: 0.044
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.041
-
A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res. 2018 12 15; 24(24):6288-6299.
Score: 0.040